Abstract | OBJECTIVES: METHODS: The systematic literature research was conducted on Medline via PubMed and the Cochrane Central Register of Controlled Trials to identify economic evaluations published before July 2018. The quality of each selected economic evaluation was assessed by two independent reviewers using the Drummond checklist. RESULTS: Our systematic review was based on 32 economic evaluations using different methodological approaches, different perspectives and different time horizons. Three-quarters of the economic evaluations are full (n = 24) with a Drummond score ≥ 7, synonymous of "high quality". Among them, 66% reported a strategy that was cost-effective. The most assessed immunotherapeutic agent was nivolumab. In patients with renal cell carcinoma or head and neck cancer, it was less likely to be cost-effective than in patients with melanoma or lung cancer. CONCLUSIONS: Whether or not these findings will be confirmed remains to be seen when market approval to cover more indications is extended and new effective immunotherapeutic agents become available.
|
Authors | Charlotte Couchoud, Philippe Fagnoni, François Aubin, Virginie Westeel, Tristan Maurina, Antoine Thiery-Vuillemin, Claire Gerard, Marie Kroemer, Christophe Borg, Samuel Limat, Virginie Nerich |
Journal | Cancer immunology, immunotherapy : CII
(Cancer Immunol Immunother)
Vol. 69
Issue 10
Pg. 1947-1958
(Oct 2020)
ISSN: 1432-0851 [Electronic] Germany |
PMID | 32676716
(Publication Type: Journal Article, Review, Systematic Review)
|
Chemical References |
- Antineoplastic Agents, Immunological
|
Topics |
- Antineoplastic Agents, Immunological
(economics, therapeutic use)
- Cost-Benefit Analysis
- Humans
- Immunotherapy
(economics)
- Neoplasms
(drug therapy, economics, immunology, pathology)
- Prognosis
|